Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Liquid Biopsies 2019

Lauren Leiman's Biography



Lauren Leiman, Executive Director, Blood Profiling Atlas in Cancer (BloodPAC)

Lauren C. Leiman is currently the Executive Director of the Blood Profiling Atlas in Cancer (BloodPAC), a consortium focused on creating an open database for liquid biopsies to accelerate the development of safe and effective blood profiling diagnostic technologies for patient benefit. Prior to running BloodPAC, she was the Senior Director of External Partnerships at White House Cancer Moonshot Task Force during the Obama Administration.

Previously, Lauren was a Senior Advisor for the Melanoma Research Alliance and Director of Philanthropy at Elysium Management LLC in New York City. From 2008-2010, Lauren worked for the Millennium Promise Alliance, where she led the major gifts fundraising effort and spent significant time in sub-Saharan Africa. Lauren was also the head of marketing and investor relations at Steel Partners, LP, an activist hedge fund investing globally.

Lauren received her undergraduate degree in communications from the University of Pennsylvania's Annenberg School. She also holds an MBA in international business from the University of North Carolina's Kenan-Flagler Business School and a master's degree in public relations and corporate communications from New York University (NYU).

Lauren Leiman Image

BloodPAC: Establishing Standards to Accelerate Development and Approval of Liquid Biopsy Technology

Friday, 29 March 2019 at 10:00

Add to Calendar ▼2019-03-29 10:00:002019-03-29 11:00:00Europe/LondonBloodPAC: Establishing Standards to Accelerate Development and Approval of Liquid Biopsy TechnologyLiquid Biopsies 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com

The Blood Profiling Atlas in Cancer (BloodPAC) looks to improve outcomes for patients with cancer through a collaborative infrastructure that enables the sharing of information between stakeholders in industry, academia and regulatory agencies. The goals of BloodPAC are: to aggregate, make freely available, and harmonize for further analysis: i) data from CTC, ctDNA, proteins including tumor associated autoantibodies, and exosome assays, ii) associated clinical data, and iii) sample collection, preparation and handling protocols.


Add to Calendar ▼2019-03-27 00:00:002019-03-29 00:00:00Europe/LondonLiquid Biopsies 2019Liquid Biopsies 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com